Tag Archives: Michael Higgins
Ladenburg Thalmann & Co. Thinks Armata Pharmaceuticals Inc’s Stock is Going to Recover
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Armata Pharmaceuticals Inc (ARMP – Research Report), with a price target of $9. The company’s shares opened today at $3.40, close to its
Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Cerecor Inc (CERC)
Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Cerecor Inc (CERC – Research Report) today and set a price target of $8. The company’s shares closed yesterday at $5.65. Higgins commented: “We reiterate our Buy rating
Palatin Technologies Inc (PTN) Received its Third Buy in a Row
After H.C. Wainwright and Canaccord Genuity gave Palatin Technologies Inc (NYSE MKT: PTN) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on Palatin Technologies
Ladenburg Thalmann & Co. Thinks Intec Pharma Ltd’s Stock is Going to Recover
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Intec Pharma Ltd (NTEC – Research Report), with a price target of $15. The company’s shares closed yesterday at $4.18, close to its
Eiger Biopharmaceuticals (EIGR) Gets a Buy Rating from Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report) today and set a price target of $28. The company’s shares closed yesterday at $10.49. Higgins commented: “We are encouraged to see
Ladenburg Thinks Novavax’s Stock is Going to Recover
Ladenburg analyst Michael Higgins maintained a Buy rating on Novavax (NVAX – Research Report) today and set a price target of $2. The company’s shares closed yesterday at $5.37, close to its 52-week low of $5.34. Higgins commented: “We don’t
